Targeting TFF1, PPA1, DKK1, LGR6, and MARCH1—while considering the tumor-suppressive role of TET1—may offer novel therapeutic avenues to overcome chemoresistance and improve patient outcomes. This evidence concerns the gene TET1 and neoplasm.